Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukocytoreduction for acute leukemia.

Pierluigi Porcu1, Sherif Farag, Guido Marcucci

  • 1Department of Medicine, Division of Hematology/Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA. porcu-1@medctr.osu.edu

Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis
|March 12, 2002
PubMed
Summary

Hyperleukocytosis in acute leukemia can cause life-threatening complications like respiratory failure due to leukostasis. Understanding leukemic blast adhesion to endothelium is key to improving outcomes for acute hyperleukocytic leukemia (AHL).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment.

Transplantation and cellular therapy·2025
Same author

Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.

Oncotarget·2025
Same author

The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission.

British journal of haematology·2025
Same author

CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors.

The Journal of clinical investigation·2025
Same author

Targeted Irradiation and STAT3 Inhibition Reprogram the AML Microenvironment and Extend Survival: Toward Translational Immunoradiotherapy.

bioRxiv : the preprint server for biology·2025
Same author

Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.

Leukemia·2025

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Acute hyperleukocytic leukemia (AHL) presents with high blast counts, leading to significant early mortality (20-40%).
  • Complications such as respiratory failure and intracranial bleeding are primarily driven by leukostasis.
  • Current understanding of leukostasis mechanisms is limited, with traditional views focusing on blast overcrowding.

Purpose of the Study:

  • To elucidate the biological mechanisms underlying leukostasis in acute hyperleukocytic leukemia.
  • To investigate the role of leukemic blast-endothelial interactions in leukostasis development.
  • To identify key molecular mediators of endothelial damage in AHL.

Main Methods:

  • Review of existing literature on hyperleukocytosis and leukostasis in acute leukemia.

Related Experiment Videos

  • Analysis of proposed mechanisms involving leukemic blast adhesion molecules and endothelial interactions.
  • Discussion of current therapeutic strategies and their limitations.

    • Main Results:

    • Leukostasis is increasingly recognized as a process driven by adhesive interactions between leukemic blasts and the endothelium, not solely by blast count.
    • Endothelial damage is likely mediated by cytokines and leukemic cell migration.
    • Adhesion molecules and chemotactic responses are more critical than blast numbers in causing leukostasis.

    Conclusions:

    • Leukostasis mechanisms involve complex cellular interactions, emphasizing adhesion over mere cell numbers.
    • Current treatments like leukocytoreduction may not fully address the underlying adhesive pathology.
    • Identifying specific adhesion molecules and cytokines is crucial for developing targeted therapies to improve outcomes in AHL.